Print Page | Sign In | Join
Business Wire Life Sciences News (US)
Share |

MiraMed Shares 2019 Circle of Warmth SuccessOpen in a New Window

JACKSON, Mich.--(BUSINESS WIRE)-- #CircleofWarmth--MiraMed Global Services, Inc. (MiraMed), a leader in healthcare business process outsourcing (BPO) solutions, is pleased to announce that its 2019 Circle of Warmth campaign has achieved resounding success. Working with the Empowerment Plan, the MiraMed Circle of Warmth had a goal to raise enough money to provide 1,000 coats to those in need throughout the country. MiraMed, as part of the MiraMed Circle of Warmth, not only met its goal, they exceeded it! The Mira

 

Anesthesia Business Consultants Shares 2019 Circle of Warmth SuccessOpen in a New Window

JACKSON, Mich.--(BUSINESS WIRE)-- #ABC--Anesthesia Business Consultants (ABC), a leading provider in billing and practice management for the anesthesia and pain management specialty, is pleased to announce that its 2019 Circle of Warmth campaign has achieved resounding success. Working with the Empowerment Plan, the MiraMed Circle of Warmth had a goal to raise enough money to provide 1,000 coats to those in need throughout the country. ABC, as part of the MiraMed Circle of Warmth, not only met its goa

 

HighRes Biosolutions and Novo Nordisk partner to transform drug discovery in automated Lab of the FutureOpen in a New Window

BEVERLY, Mass.--(BUSINESS WIRE)--HighRes Biosolutions and Novo Nordisk A/S announce they will collaborate to design a robotic platform for high-throughput biologics characterization

 

ProtoKinetix Takes Delivery of GMP AAGP® PKX-001 Dedicated for Phase 1 TrialOpen in a New Window

MARIETTA, Ohio--(BUSINESS WIRE)-- #AAGP--ProtoKinetix Takes Delivery of GMP AAGP® PKX-001 Dedicated for Phase 1 Trial

 

Decibel Therapeutics to Present at the 43rd Annual Association for Research in Otolaryngology (ARO) ConferenceOpen in a New Window

BOSTON--(BUSINESS WIRE)--Decibel Therapeutics will present new findings at the 43rd annual meeting of the Association for Research in Otolaryngology in San Jose, CA.

 

Moog Announces Cash DividendOpen in a New Window

EAST AURORA, N.Y.--(BUSINESS WIRE)--MOOG ANNOUNCES CASH DIVIDEND

 

Co-Diagnostics Announces $5.0 Million Registered Direct Offering Priced At-the-MarketOpen in a New Window

SALT LAKE CITY--(BUSINESS WIRE)---- $CODX #CODX--Co-Diagnostics announces $5.0 Million registered direct offering, following news about beginning work on a test for the new coronavirus.

 

Alpine Immune Sciences Presents New Preclinical Data at 2020 Crohn’s & Colitis Congress   ALPN-101 demonstrates efficacy in treatment of chronic inflammatory bowel disease in both in vivo and in vitro modelsOpen in a New Window

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, presented new preclinical data on its lead autoimmune/inflammatory clinical program, ALPN-101, at the 2020 Crohn’s & Colitis Congress in Austin, Texas. ALPN-101 is a novel inhibitor of both the CD28 and ICOS T cell co-stimulatory pathways on both naïve and activated pathogenic T cells

 

Enanta to Host Conference Call on February 6 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal First Quarter Ended December 31, 2019Open in a New Window

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating and developing small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2019, after the U.S. markets close on February 6, 2020. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enan

 

Exelixis Announces Results for Combination of Cabozantinib and Nivolumab With or Without Ipilimumab in Advanced Hepatocellular CarcinomaOpen in a New Window

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced phase 1/2 clinical trial results from the combination of cabozantinib (CABOMETYX®) and nivolumab (Opdivo®) with or without ipilimumab (Yervoy®) in advanced hepatocellular carcinoma (HCC). Data from the cabozantinib combination cohort of the CheckMate 040 trial will be presented on Friday, January 24 during Rapid Abstract Session B from 7:00 – 7:45 a.m. PT at the 2020 American Society of Clinical Oncology’s Gastroint

 

Beam Therapeutics Promotes Giuseppe Ciaramella, Ph.D., to President and Chief Scientific OfficerOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced the promotion of chief scientific officer Giuseppe “Pino” Ciaramella, Ph.D., to president. Dr. Ciaramella will continue his role as chief scientific officer. “Pino has been an exceptional leader at Beam from day one, leading the growth of our base editing platform and pipeline,” said John Evans, chief executive officer of Beam. “Pino will be

 

Amneal to Report Fourth Quarter and Full Year 2019 Results on February 26, 2020Open in a New Window

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE:AMRX) announced today that the Company will release its fourth quarter and full year 2019 financial results on Wednesday, February 26, 2020, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on February 26, 2020. The financial results and live webcast will be accessible through the Investor Relations section of the

 

2020 U.S. Molecular Diagnostics Market: Agilent Technologies, Decode Genetics, Roche, Scienion &Thermo Fisher - ResearchAndMarkets.comOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "2020 U.S. Molecular Diagnostics Market: Sales and Market Shares of Major Suppliers, Strategic Profiles of Leading Competitors and Emerging Market Entrants" report has been added to ResearchAndMarkets.com's offering. This unique report from the author provides US sales and market share estimates for major suppliers of molecular diagnostic products. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product

 

UPDATED TIME: Alexion Fourth Quarter and Full Year 2019 Results Conference Call at 7:30am ET on Thursday, January 30, 2020Open in a New Window

BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that it has updated the time of its fourth quarter and full year 2019 earnings call on January 30, 2020 to 7:30 a.m. Eastern Time. The call had previously been scheduled for 8:00 a.m. ET. All other aspects of the call remain unchanged. The Company will report its financial results for the fourth quarter and full year ended December 31, 2019 before the US financial markets open on January 30, 2020. To participa

 

First Databank Names Brian Taylor Vice President of SalesOpen in a New Window

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DigitalHealth--First Databank (FDB), the leading provider of drug and medical device knowledge, names Brian Taylor vice president of sales for North America.

 

Lysogene Announces Its Corporate Agenda For 2020Open in a New Window

PARIS--(BUSINESS WIRE)--Regulatory News: Lysogene (Paris:LYS) (FR0013233475 – LYS) today announced its corporate agenda* for 2020: 17 February 2020: Sales and cash position at the end of 2019 20 March 2020: 2019 annual results 22 April 2020: First quarter 2020 sales and cash position June 2020 (day to be confirmed later): General shareholders’ meeting 24 July 2020: Sales and cash position for the first half 2020 25 September 2020: First half 2020 results 19 November 2020: First nine months 2020

 

Genentech Provides an Update on Phase III Study of Tecentriq in People With Muscle-invasive Urothelial CancerOpen in a New Window

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab) as an adjuvant (after surgery) monotherapy treatment did not meet its primary endpoint of disease-free survival (DFS) compared to observation in people with muscle-invasive urothelial cancer (MIUC). Safety for Tecentriq appeared consistent with the known safety profile of the medicine, and no n

 

Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for the Treatment of Patients with Epithelioid SarcomaOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma

 

MyndVR Announces Partnership with Vi at Palo AltoOpen in a New Window

PALO ALTO, Calif.--(BUSINESS WIRE)--MyndVR, the national leader in providing virtual reality (VR) solutions for senior living communities, announced today that it has signed a partnership with Vi, Palo Alto’s premier continuing care retirement community (CCRC). Vi provides residents with independent living as well as a full continuum of care, with 10 communities across the U.S. Vi is launching MyndVR’s state-of-the art VR platform at its Palo Alto community as an entertainment offering that com

 

New Coalition Will Help Hospitals Provide Plant-Based Meals in 2020Open in a New Window

WASHINGTON--(BUSINESS WIRE)--Cheesy scrambled eggs, meatloaf, and chicken parmesan. It’s not unusual for hospitals to serve meals like these to heart disease and stroke patients. But in 2020, a new coalition is helping hospitals nationwide provide patients plant-based food options that combat rather than contribute to cancer, diabetes, obesity, and heart disease. The Physicians Committee for Responsible Medicine, the Humane Society of the United States, Oldways, Health Care Without Harm, and Me

 

PerkinElmer Board Declares Quarterly DividendOpen in a New Window

WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), declared a regular quarterly dividend of $0.07 per share of common stock on January 23, 2020. This dividend is payable on May 8, 2020 to all shareholders of record at the close of business on April 17, 2020. About PerkinElmer PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $2.8 billion in 2018, has about 13,000 employees servin

 

Acceleron Announces Change to Executive Management TeamOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that John Quisel, J.D., Ph.D, Executive Vice President and Chief Business Officer, is leaving the Company to become Chief Executive Officer of a venture-backed startup biotechnology company. Dr. Quisel’s departure from Acceleron is effective as of February 24. “John ha

 

NextGen Healthcare, Inc. Reports Fiscal 2020 Third QuarterOpen in a New Window

IRVINE, Calif.--(BUSINESS WIRE)--NextGen Healthcare, Inc. (NASDAQ: NXGN), a leading provider of ambulatory-focused healthcare technology solutions, announced today its fiscal 2020 third quarter ended December 31, 2019 operating results. Fiscal 2020 Third Quarter Highlights On a GAAP basis, revenue for the fiscal 2020 third quarter was $137.7 million compared to $130.9 million a year ago. On a GAAP basis, net income for the fiscal 2020 third quarter was $4.4 million compared with net income of $

 

CBSET-CILcare to Report Experimental Methodologies for Performing Translational Auditory Research in Pigs and Sheep at the ‘ARO Midwinter Meeting’Open in a New Window

LEXINGTON, Mass.--(BUSINESS WIRE)--CBSET-CILcare to report experimental methodologies for performing translational auditory research in pigs and sheep at the ‘ARO Midwinter Meeting’

 

President Bill Clinton to Keynote 2020 World Patient Safety, Science & Technology SummitOpen in a New Window

IRVINE, Calif.--(BUSINESS WIRE)--President Bill Clinton, the 42nd President of the United States, will be the closing keynote speaker at the Patient Safety Movement Foundation’s 2020 World Patient Safety, Science & Technology Summit. The 8th annual Summit will be held in Huntington Beach, California, beginning with a Pre-Summit Symposium on Thursday, March 5th. At the 2020 Summit, hospital leaders, medical and information technology innovators, patient advocates, policy makers and governmen

 

Anemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to Phacilitate Leaders World 2020 in MiamiOpen in a New Window

MIAMI--(BUSINESS WIRE)--Anemocyte, an innovative Italian company working in the field of cell and gene therapies, with special focus on plasmid production and non-viral gene modification approaches, attends Phacilitate Leaders World (Miami, 21-24 January 2020), a leading event for companies, professionals and investors working in the Advanced Therapy sector. “Phacilitate Leaders World is an opportunity to take stock of this sector, which is in constant evolution”, states Marco Ferrari, CEO of A

 

L2P Research (Former AJES Life Sciences, LLC) and Transcell Oncologics, LLC Announce Partnership to Provide High Quality Hu-CB-CD34 and Hu-PBMC to Generate Humanized Mouse Models for ResearchOpen in a New Window

ANNVILLE, Pa.--(BUSINESS WIRE)--L2P Research, LLC and Transcell Oncologics, LLC have entered into a partnership with the purpose of marketing and the distribution of Transcell Oncologics, LLC Trans HSC (CD34+), Trans-HSC (PBMC) product line and L2P Research’s humanized mouse models. L2P Research, LLC is a Pennsylvania based Research organization founded with a vision to provide integrated R&D support in all the key areas of Pharmaceutical development. L2P provides a complete array of resear

 

Riversand Positioned as the Only Visionary in Gartner Magic Quadrant Report for Master Data Management SolutionsOpen in a New Window

HOUSTON--(BUSINESS WIRE)--Riversand, a leading SaaS Master Data Management (MDM) and Product Information Management (PIM) solution provider, announced today that Gartner, Inc., a global research and advisory firm, positioned Riversand in the Visionaries quadrant in the Magic Quadrant for Master Data Management Solutions, published on Jan. 13, 2020. Riversand is the only MDM solution provider listed as a Visionary for the fourth consecutive time. Read a complimentary copy of the Gartner Magic Qu

 

About BioFlorida

BioFlorida represents 6,200 establishments and research organizations in the biopharmaceuticals, medical technology, healthIT and bioagriculture sectors that collectively employ 87,000 Floridians.

 

Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors and service providers.

 

NEW regional sponsorship opportunities available.

Connect